1. Scrip
  2. >>Therapy Areas
  3. >>Musculoskeletal

Tonix reverses into US public shell, raising $1.1 million and questions

 
• By Nancy Faigen

Tonix Pharmaceuticals, a specialty pharma company focused on CNS disorders and based in New York City, has completed a reverse merger transaction through a share exchange agreement with publicly traded Tamandare Explorations Inc. Through a share exchange, the shareholders of Tonix acquired control of Tamandare.

Tonix Pharmaceuticals, a specialty pharma company focused on CNS disorders and based in New York City, has completed a reverse merger transaction through a share exchange agreement with publicly traded Tamandare Explorations Inc. Through a share exchange, the shareholders of Tonix acquired control of Tamandare.

In addition, Tamandare completed a private placement of $1.1 million to fund further R&D. Tamandare intends to change its name...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Musculoskeletal

Sarepta Expects Tighter Elevidys Label As Amondys/Vyondys Study Sputters

 
• By Alaric DeArment

The company’s third quarter earnings fell by $67.8m year-over-year, reflecting the tumultuous situation around its DMD therapy Elevidys in June.

BridgeBio Thinks Its Phase III Limb-Girdle MD Data Could Support Full Approval

 
• By Joseph Haas

Despite a prior agreement with the FDA to seek accelerated approval, with Phase III data showing statistical significance on biomarkers and functional measures, BridgeBio is aiming higher.

Novartis Makes Its Biggest Bet In A Decade With $12bn Avidity Deal

 
• By Manas Mishra

The deal comes on the back of promising data from Avidity's next-generation RNA therapeutics over the past two years and a subsequent meteoric rise in share value.

New Biopharma Elevara Launched With CD4/6 Inhibitor For Rheumatoid Arthritis

 
• By Andrew McConaghie

With a mechanism better known for its use in breast cancer, Elevara believes its CDK4/6 inhibitor candidate could help more patients with rheumatoid arthritis reach complete remission.

More from Therapeutic Category

Lilly’s Eloralintide Success Sets Bar For Amylin Rivals

 
• By Andrew McConaghie

The US pharma giant may have a best-in-class amylin agonist to go with incretin blockbuster Zepbound, but challengers could still go one better on safety and tolerability.

Lilly, Novo Lower US Obesity Drug Prices To Secure Government Coverage

 
• By Jessica Merrill

Wegovy and Zepbound will cost around $250 per month under Medicare and Medicaid, and the drugs will cost around $350 per month through TrumpRx.

Lilly Plans Phase III Trials After Positive Results From Amylin Drug Eloralintide

 
• By Alaric DeArment

The drugmaker presented positive data from its Phase II study at ObesityWeek that help validate the amylin class overall, which includes more than a dozen entrants.